CERO
CERO THERAPEUTICS HOLDINGS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Nov 18 ▼ D. Boral Capital downgrades
- Mar 11 ▼ CERO Therapeutics raised $750,000 through a convertible promissory n…
- Jun 26 ▼ CERO Therapeutics entered into an amended and restated convertible p…
- Jul 13 ▼ Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics'…
- Aug 14 ▲ Short interest falls 95.2% to 1.0K
- Aug 31 ▼ CERO Therapeutics completed a secured financing with SRX Global, con…
- Aug 31 ▼ Short interest jumps 3485.7% to 36.1K
- Sep 15 ▲ Short interest falls 93.1% to 2.5K
- Sep 30 ▼ Short interest jumps 397.5% to 12.4K
- Oct 7 ▼ CERO Therapeutics Holdings has agreed to sell its wholly-owned opera…
- Oct 15 ▲ Short interest falls 91.9% to 1.0K
- Oct 30 ▼ Short interest jumps 1911.5% to 20.2K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2025: 1 added (0 new), 1 trimmed or exited.
- Short sellersBUILDING
Short interest +1911.5% to 20.2K shares. 1.0 days to cover.
- TrendDOWNTREND
36% below its 50-day average.
Who's buying
13F· Q3 2025| Fund | Move | Value |
|---|---|---|
| UBS Group AG | NEAR_EXIT | $30.00 |
| BANK OF AMERICA CORP /DE/ | ADD | $15.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Nov 2025| Date | Firm | Rating |
|---|---|---|
| Nov 18, 2025 | D. Boral Capital DOWNGRADE | Hold |
| Oct 30, 2025 | D. Boral Capital MAINTAIN | Buy |
| Oct 22, 2025 | D. Boral Capital MAINTAIN | Buy |
| Oct 13, 2025 | D. Boral Capital MAINTAIN | Buy |
| Sep 23, 2025 | D. Boral Capital MAINTAIN | Buy |
| Sep 9, 2025 | D. Boral Capital MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Francois Eric Director Mar 4, 2026 | AWARD | 1,823,278 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 0 bullish · 5 bearish- BEARISH 8-KOct 7, 2026
CERO Therapeutics Holdings has agreed to sell its wholly-owned operating subsidiary (CERo…
CERO common stock becomes a shell holding SRX shares post-close, with a 180-day lock-up preventing immediate liquidation. The go-shop period runs through ~Nov 5, 2026, monitor for any superior…
- BEARISH 8-KAug 31, 2026
CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior…
This is a distressed bridge loan with a 7-week maturity, the company must either repay, refinance, or face default by mid-October. The secured position of SRX (first lien on all subsidiary IP and…
- BEARISH 25-NSEJul 13, 2026
Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics' securities from listing and…
The delisting is now irrevocable. Expect continued deterioration in liquidity and possible SEC deregistration (Form 15) which would halt public reporting. Existing OTC holders face minimal catalyst…
- BEARISH 8-KJun 26, 2026
CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health…
Expect continued downward pressure from the overhang of potential conversion shares, as the lender can convert at a deep discount to market. Monitor for the registration statement filing (due by…
All CERO filing & press-release reports (5)
- 8-K reportOct 7, 2026
- 8-K reportAug 31, 2026
- 25-NSE reportJul 13, 2026
- 8-K reportJun 26, 2026
- 8-K reportMar 11, 2026